Spero Therapeutics Enters into a License Agreement with Pfizer for SPR206 to Treat MDR Gram Negative Infections
Shots:
- Spero is eligible to receive $40M as an equity investment and ~$80M as development & sales milestones along with royalties on sales of SPR206 in licensed countries. Pfizer gets rights to develop- manufacture & commercialize SPR206 in ex-US & ex-Asia
- As per the 2019 licensing agreement with Spero- Everest Medicines has exclusive rights to develop- manufacture & commercialize SPR206 in Greater China- South Korea & other Southeast Asian countries for MDR gram-negative bacterial infections
- In Jan’21- an agreement was amended for assignment of relevant SPR206 patents to Everest in the licensed territories while agreement b/w Spero & Pfizer have no impact on Everest's rights for SPR206
| Ref: PR Newswire | Image: Cowen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
